# Dr. Marty Makary

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/dr-marty-makary
Canonical HTML page: https://gethealthbrief.com/entity/dr-marty-makary

## Timeline

- **2026-07-16**: FDA approves Merck's Lipfendra — The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
- **2026-05**: Marty Makary resigns as FDA Commissioner — Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.

## Recent coverage (1 stories)

### Merck's Lipfendra: 59% LDL Cut with First Oral PCSK9 Pill Approved
2026-07-16 23:20:10 · Sentiment: Bullish · Impact: 8/10 · Sources: 7

The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Full story: https://gethealthbrief.com/story/merck-lipfendra-oral-pcsk9-pill-59-percent-ldl-cut-health-systems

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.